TY - JOUR
T1 - Ketanserin effects on insulin sensitivity in nonobese, nondiabetic hypertensive patients
T2 - An evaluation by the euglycemic-hyperinsulinemic clamp technique
AU - Fogari, R.
AU - Zoppi, A.
AU - Derosa, G.
AU - Lusardi, P.
AU - Mugellini, A.
AU - Lazzari, P.
PY - 1995
Y1 - 1995
N2 - The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients. Eleven nonobese, nondiabetic mild to moderate hypertensives (6 males, 5 females, aged 39-59 years), after a 4 week run-in period on placebo, were treated with ketanserin 40 mg twice daily for 12 weeks. Blood pressure (BP) (by standard mercury sphygmomanometer) and insulin sensitivity (by the euglycemic hyperinsulinemic clamp technique) were evaluated at the end of the placebo period and at the end of the treatment period. Ketanserin produced a significant decrease in BP (from 160 ± 13/100 ± 4 mmHg to 146 ± 10/89 ± 5 mmHg p <0.01). The amounts of exogenous glucose required to hold glucose levels constant during clamp were not changed by ketanserin as compared to placebo 34.5 ± 3.5 g vs 33.8 ± 3.1 g). The rate of glucose infusion required during the last 60 minutes of the clamp, used as an indicator of insulin sensitivity, was not different before and after treatment (5.52 ± 0.41 mg/min/kg vs 5.21 ± 0.39 mg/min/kg). These results suggest that in nonobese, nondiabetic hypertensive patients ketanserin monotherapy is effective in reducing BP values without affecting insulin sensitivity.
AB - The aim of this study was to assess the effects of ketanserin on insulin resistance in nondiabetic hypertensive patients. Eleven nonobese, nondiabetic mild to moderate hypertensives (6 males, 5 females, aged 39-59 years), after a 4 week run-in period on placebo, were treated with ketanserin 40 mg twice daily for 12 weeks. Blood pressure (BP) (by standard mercury sphygmomanometer) and insulin sensitivity (by the euglycemic hyperinsulinemic clamp technique) were evaluated at the end of the placebo period and at the end of the treatment period. Ketanserin produced a significant decrease in BP (from 160 ± 13/100 ± 4 mmHg to 146 ± 10/89 ± 5 mmHg p <0.01). The amounts of exogenous glucose required to hold glucose levels constant during clamp were not changed by ketanserin as compared to placebo 34.5 ± 3.5 g vs 33.8 ± 3.1 g). The rate of glucose infusion required during the last 60 minutes of the clamp, used as an indicator of insulin sensitivity, was not different before and after treatment (5.52 ± 0.41 mg/min/kg vs 5.21 ± 0.39 mg/min/kg). These results suggest that in nonobese, nondiabetic hypertensive patients ketanserin monotherapy is effective in reducing BP values without affecting insulin sensitivity.
KW - Hypertension
KW - Insulin sensitivity
KW - Ketanserin
UR - http://www.scopus.com/inward/record.url?scp=0029146722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029146722&partnerID=8YFLogxK
M3 - Article
C2 - 8556225
AN - SCOPUS:0029146722
VL - 33
SP - 453
EP - 456
JO - International Journal of Clinical Pharmacology and Therapeutics
JF - International Journal of Clinical Pharmacology and Therapeutics
SN - 0174-4879
IS - 8
ER -